drug

Loopholes, Lack Of Staffing Stymie Transparency Of Oregon’s Drug Pricing Program

This article is for premium subscribers. Please sign up here for a tax-deductible subscription. 

If you're a premium subscriber, sign in below. 

The state’s Prescription Drug Price Transparency Program was created to illuminate pharmaceutical pricing practices, but pharmaceutical companies have shielded information they say infringes on trade secrets.

Nosse and Steiner Hayward Back Mandatory Rebates for High-Cost Drugs

The Oregon Department of Consumer and Business Services would step in if a drug exceeded $10,000 or had cost increases greater than 3.4 percent. State regulators would index a price according to what other countries have negotiated for the drugs. Consumers would also see a cap on costs that they pay out-of-pocket.

Rep. Rob Nosse, D-Portland, touted his aggressive and innovative approach to tackling uncontrolled pharmaceutical costs on Thursday, calling on Oregon to lead where Congress has failed and other state-based reforms have fallen short.

Subscribe to drug